

SALSS D.C. 2019 SPEAKER PROFILES



BIBLIOGRAPHY

SPEAKERS PAGE 3
SENIOR ADVISORY BOARD PAGE 11
ORGANIZING COMMITTEE PAGE 11
SALSS ON SOCIAL MEDIA PAGE 11

SPEAKER INDEX

IN ALPHABETICAL ORDER

DR. GARO ARMEN, PAGE 4
MR. KARL BERGMAN, PAGE 9
DR. JENNIFER BUELL, PAGE 9
MS. MERYL COMER, PAGE 5
DR. CARLOS DE SOUSA, PAGE 9
THE HONORABLE DIANA DEGETTE, PAGE 4
MS. BARBRO C. EHNBOOM, PAGE 3
MR. STEVEN EROR, PAGE 6
DR. RICHARD HAUSMANN, PAGE 8
MR. SEBASTIAN HERMELIN, PAGE 10
PROFESSOR HENRIC JOHNSON, PAGE 3
DR. PETER M. KASH, PAGE 5
DR. ANNA MARONEY, PAGE 6
DR. DEBORAH MASH, PAGE 7
DR. JENNI NORDBORG, PAGE 4
DR. ALEXANDER W. NUYKEN, PAGE 5
DR. ANN ROSE, PAGE 6
MR. GREGORY C. SIMON, PAGE 8
DR. EUGEN STEINER, PAGE 6
MS. MARIA TUFVESSON SHUCK, PAGE 7
MS. HELÉN WAXBERG, PAGE 7



SPEAKERS

IN THE ORDER OF APPEARANCE IN THE PROGRAM



Ms. Barbro C. Ehnbom

Founder & Chairman, Swedish-American Life Science Summit

Founder and Chairwoman of the Swedish-American Life Science Summit, Ms. Ehnbom has been a pioneer in the Life Science industry throughout her entire career. She was one of the first female executives in the U.S. pharmaceutical industry and one of Wall Street's top analysts. She worked several years as an investment banker at Wasserstein Perella, which at the time was the world's leading investment bank, where she led the bank's M&A activities in Scandinavia. Ms. Ehnbom has served as a board member of the Swedish-American Chamber of Commerce and Chairman Emeritus of the Swedish Economist Group in New York many years, and has long experience in creating successful financial cross border collaborations. In addition to Ms. Ehnbom's drive for the commercial field, she is highly committed to and passionate about academia, music, the arts and social entrepreneurship. She is the founder of the prestigious scholarship Female Economist of the Year at her alma mater Stockholm School of Economics. Through the scholarship and the network Barbro's Best & Brightest (BBB) she has successfully supported and promoted young women in business over the past 20 years.



Professor Henric Johnson

Science & Innovation Counselor, Embassy of Sweden to the United States

Henric Johnson is a professor and an academic entrepreneur with many years of applied experience in industry and academia (and the collaboration between these organizations). He has a background in Computer Science with a focus on security and social computing. Johnson is currently a Diplomat and the Swedish Science and Innovation Counselor to the United States. He was previously a Visiting Scholar at Stanford University and a Senior Wallenberg Fellow at the Nordic Innovation House, Palo Alto. Johnson has also been part of the Stanford Academy Leadership Program and the Stanford Fellow program.

Johnson has been an academic leader for several years in the position as Pro Vice-Chancellor (Provost) at Blekinge Institute of Technology (BTH), one of the most profiled University in Sweden. At BTH, Johnson has also been the Head of a Department of Technology and Aesthetics. He has also been the Director for the Center for Electronic Security and an initiator of the Blue Science Park in Sweden.

Johnson has a well-established network in Europe and the United States, and collaborates with several research groups, industry partners, profit and non-profit organizations worldwide. He has been a research scientist at the Advanced Research and Development Department at Ericsson in the Research Triangle Park, North Carolina and also been part of a Biometric startup company. He has studied at Virginia Tech and been a visiting scholar at the Security Lab at the University of California Davis. For his research results and impact in the industry, he has been awarded The TelecomCity Prize, Teacher of the Year and the Ericsson Research Foundation Award. Professor Johnson is frequently invited to lecture in many different contexts (e.g., the Swedish Parliament and large global corporations).

His current research interest is on trust, disinformation, fake news and computational propaganda. In Sweden, Johnson also developed an innovative and sustainable farm with High Land Cattles.

SPEAKERS



The Honorable Diana DeGette

Member of Congress

Congresswoman Diana DeGette represents Colorado's 1st Congressional district and has established herself as a leader in Colorado and on the national stage. She proudly stands on the frontlines for progressive change on health care, reproductive rights, climate change, consumer protection and the environment.

Congresswoman DeGette serves as a senior member of the powerful Committee on Energy and Commerce where she has leveraged her leadership position to improve health care, expand medical research, reform corporate business and accounting practices, take on global climate change, and move America toward energy independence. In 2019, she was named Chair of the Subcommittee on Oversight and Investigations, putting her in a position to hold Administration officials accountable. She also serves on the Committee on Natural Resources, where she has fought to protect America's public lands and has been a strong advocate for energy policies that seek to protect the country's precious resources.

In addition to her committee assignments, Congresswoman DeGette is the Co-Chair of the Congressional Pro-Choice Caucus and Chair of the Congressional Diabetes Caucus.

Congresswoman DeGette received her B.A. magna cum laude from Colorado College in 1979 and her J.D. from New York University School of Law in 1982. She served two terms in the Colorado House of Representatives serving as Assistant Minority Leader from 1993-1995.



Dr. Jenni Nordborg

Director, National Coordinator Life Sciences, Government Offices of Sweden

Dr. Jenni Nordborg, Ph.D., is National Coordinator and Director of Life Sciences at the Government Offices of Sweden, heading the Office for Life Sciences, and is responsible for forming a new Swedish Life Science Strategy. Dr. Nordborg is also Director and Head of the Health Division at Vinnova, the Swedish Governmental Innovation Agency. She is active in strategic innovation policy development and implementation within health and life science on national and international level. Dr. Nordborg has a research background from

Chalmers University of Technology and worked at several international high-level research facilities in Japan, USA, Australia and Europe. She has experience in start-up, management and marketing and sales of a growing high-tech business with global market. She also has experience in board level positions both in private companies and governmental organizations, and is Member of the Board of Nordic Innovation.



Dr. Garo Armen

Chairman & CEO, Agenus

Garo serves as Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products for 20 years. From mid-2002 through 2004, Garo, in addition to his responsibilities at Agenus, served as Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Garo serves as non-executive Chairman of the Board of Protagenic

Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of neurological and metabolic disorders. He also serves as Founder and Chairman of the Children of Armenia Fund (COAF), a philanthropic organization he founded in 2000; COAF is dedicated to the development of children and youth in Rural Armenia. He received his PhD in physical chemistry from the City University of New York.

SPEAKERS



Dr. Alexander W. Nuyken

Partner, EY

Dr. Alexander W Nuyken is a Partner at Ernst & Young GmbH and heads EY EMEIA Center for Life Sciences, a group within EY that focuses on M&A and portfolio strategy in pharma and medtech. He has over 15 years' international M&A experience in the sector, including two as an M&A lawyer and 10 in healthcare investment banking with Lehman Brothers, Nomura and UBS, where he had account leadership roles for various large cap pharma clients. He has worked on a significant number of transactions in

pharma and medtech, including buy-side and sell-side M&A and capital market transactions. His clients include Bayer, Boehringer Ingelheim, Fresenius, Novartis, Roche, and various small and midcap clients. Alex holds an MBA from INSEAD.



Ms. Meryl Comer

President & CEO, Geoffrey Beene Foundation Alzheimer's Initiative | Co-Founder, Global Alliance on Women's BrainHealth

Ms. Meryl Comer is President and CEO of Geoffrey Beene Foundation Alzheimer's Initiative, which promotes early diagnosis, virtual innovation challenges and mHealth technologies. A founding partner of The Global Alliance on Women's Brain Health and co-founder of Women Against Alzheimer's, she serves on the NIH National Advisory Council on Aging (NACA). In 2012, she led the formation of the 21st Century

BrainTrust® (21CBT), a non-profit partnership to advance mobile health technologies and brain health. Comer is also co-principal investigator for the PCORI Alzheimer's Patient/Caregiver Research Network in partnership with the Mayo Clinic, UCSF's Brain Health Registry, and USAgainstAlzheimer's Networks. Comer served on the bipartisan Alzheimer's Study Group, charged with presenting a National Strategic Plan to Congress. A former veteran broadcast journalist, Comer's New York Times bestseller, *Slow Dancing with a Stranger* (HarperCollins) supports Alzheimer's research.



Dr. Peter M. Kash

Vice-Chairman & Co-Founder, TargImmune Therapeutics

Dr. Peter Kash is Vice Chairman and Co-Founder of TargImmune Therapeutics. He is a global biotech entrepreneur and has raised significant capital for private biotech companies. He has co-founded more than a dozen companies and his former investment banks financed several blockbuster biotech firms including Keryx, Intercept, Kite, Cougar and Velcera. Collectively the companies he co-founded have 6 FDA approved drugs.

Dr. Kash was an Adjunct Professor of Entrepreneurship at Wharton School of Business and has been a visiting professor at several other leading universities including Hebrew University in Israel and Nihon University in Japan. He has authored several books including the international best seller *Make Your Own Luck* (2001), translated into 8 languages and distributed in more than 30 countries. In (2007) he co-authored *Freedom from Disease and Take Two Tablets Medicine from the Bible* (2014).

Dr. Kash holds a BSc in Management Science, an MBA in Banking and International Finance and a Doctorate in Education.

SPEAKERS



Dr. Anna Maroney

Vice President, Alliance Management, Abbvie

Dr. Anna Maroney has served as Vice President, Head of Alliance Management for AbbVie since 2013. Dr. Maroney has over 25 years of experience in drug discovery and clinical development with a unique blend of biotech and large pharma research and business development. Prior to joining AbbVie, she had executive roles in business development and clinical leadership at GSK, where she was Head of the U.S. Site for the Center of Excellence for External Drug Discovery and a Medicine Development Leader on a late-stage clinical asset.

Earlier career experiences in R&D Project Leader roles include Johnson & Johnson PRD, 3-Dimensional Pharmaceuticals and Cephalon Inc. She earned her Ph.D. in biochemistry at the University of Rochester and completed her post-doctoral fellowship at the University of Pennsylvania as a Howard Hughes Fellow.



Dr. Eugen Steiner

Venture Partner, HealthCap

Dr. Steiner has over 30 years executive management experience as CEO or executive chairman in development stage life science companies. As a venture partner of HealthCap, a leading European healthcare venture capital fund, he has since 1997 successfully organized and managed several start-up teams in companies which have been financed in part by HealthCap and has led financing efforts in these, which have succeeded in raising in total of over 500 million SEK from Swedish, European and US investors, enabling those companies to execute their strategies and to grow. Dr. Steiner is on the board of several public and private life science companies as well as of the Stockholm School of Entrepreneurship. Until 1987, Dr. Steiner practiced medicine and was active in pharmacological research at the Karolinska Hospital, Sweden. Dr. Steiner received his medical degree from Karolinska Institute, and earned a Ph.D. in Clinical Pharmacology.



Mr. Steven Eror

Strategic Investor, Hill Top Group

Mr. Steven Eror serves as Strategic Investor at the Hill Top Group. Mr. Eror is an experienced business builder and business development professional with leadership in Predictive Analytics, Drug Delivery, Medical Devices, Business Development, Entrepreneurship, and Strategic Planning.

Mr. Eror's previous appointments include CEO of ProLung, MacroMed and Consonus. He has also serves as Adjunct Professor of Finance at the David Eccles Graduate School at the University of Utah. Mr. Eror holds an MBA in finance, as well as a BA in economics and French from the University of Utah.

SPEAKERS



Dr. Ann Rose

CEO & President, Regulatory, ViCRO

Dr. Ann Rose is founder, CEO/President of ViCro, a company founded in 1998. She has over 20 years experience in drug/device/OTC development from a regulatory, clinical and business development aspect both in government and the private sector. During her government experience in the Congress of the U.S. (OTA) and the Department of Health & Human Services (Office of the Secretary and Assistant Secretary for Health) she rose to the position of Deputy to the Science Advisor. Dr. Rose was a principal in several key pieces of legislation affecting the PHS, e.g. the Orphan Products Act of 1983 and the Technology Transfer Act of 1986 and instrumental in licensing the first AIDS invention @ NIH to the private sector. She rose to senior corporate executive positions in major pharmaceutical e.g. AKZO and biotech companies e.g. OSI Pharma providing leadership and guidance for drug development and regulatory affairs. Rose received her doctorate in epidemiology and public health from the University of Texas. She has published numerous articles in peer-reviewed journals on these topics and speaks extensively at professional meetings. A recipient of several awards from the National Science Foundation, the University of Texas and the Sigma Xi Award for Outstanding Research. She also serves on the Boards of several organizations.



Ms. Helén Waxberg

Senior Advisor, Life Sciences, Mannheimer Swartling

Ms. Helen Waxberg is Senior Adviser at Mannheimer Swartling Advokatbyrå AB, Sweden and was chair of the firm's Life Sciences Group 2006-2019. She chairs the National Marketing and Advertising Committee of ICC Sweden and is a member of the Swedish Anti-Corruption Institute's Ethics Committee. Ms. Waxberg works primarily with regulatory issues, marketing and distribution in the pharmaceutical, biotech, medtech and health care industries and other regulated industries such as foods and cosmetics. Ms Waxberg's practice encompasses the full range of industry matters including co-operation between the industry and HCPs, marketing, sponsoring, reimbursement, pricing and other market access issues, substitution, product recalls etc. Ms. Waxberg regularly assists the industry in matters handled by the industry's self-regulatory bodies and cases before authorities and administrative courts. Her work also focuses on corporate entertainment, anti-corruption and related issues in the Life Sciences industry. Ms. Waxberg is often engaged as speaker at seminars and conferences.



Ms. Maria Tufvesson Shuck

Partner, Mannheimer Swartling

Ms. Maria Tufvesson Shuck is head of Mannheimer Swartling's New York office and she has more than 20 years' experience of Swedish-American cross border legal matters, in particular within the areas of Securities Law and Swedish companies' establishments and acquisitions in the United States.

Ms. Tufvesson Shuck received an LL.M from Harvard Law School in 1987 and an LL.M from Lund University in 1985. Ms. Tufvesson Shuck is a member of the Swedish and the New York bars and serves as a director on the boards of several Swedish-American organisations and foundations.

SPEAKERS



Dr. Deborah Mash


Professor of Neurology (Emeritus), University of Miami | CEO & Founder DemeRx

Dr. Deborah Mash is Professor Emeritus of Neurology and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine and founder of the University's Brain Endowment Bank. Further, she is Professor of Biomedical Sciences at the Patel College of Medicine Nova Southeastern University. Dr. Mash is also the CEO and Founder of DemeRx. She is a neuroscientist, lecturer, and inventor who has dedicated more than 30 years of research to unlocking the secrets of the human brain.

Dr. Mash is nationally recognized as a leading researcher in neuroscience and brain disorders, playing a pivotal role in more than 250 published studies investigating aging, neurodegenerative and neuropsychiatric diseases. Dr. Mash received her Ph.D. in Neuropharmacology and Neuroscience from the University of Miami Leonard M. Miller School of Medicine and completed her postdoctoral fellowship in Neurology and Neuroanatomy at the Harvard Medical School.

Ms. Meryl Comer

President & CEO, Geoffrey Beene Foundation Alzheimer's Initiative | Co-Founder, Global Alliance on Women's BrainHealth
See page 5.



Mr. Gregory C. Simon

President, Biden Cancer Initiative

Mr. Greg Simon served as the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. Over nine months, Mr. Simon and his team helped launch over seventy innovative collaborations.

In his career, Mr. Simon has held senior positions in both chambers of Congress, was Chief Domestic Policy Advisor to Vice President Al Gore, was a senior strategy consultant to a variety of international technology CEO's, co-founded and led FasterCures and the Melanoma Research Alliance, was the Senior Vice President at Pfizer for worldwide policy and public engagement and was the CEO of Poliwoog, a financial services company creating unique capital market opportunities in healthcare and life sciences. He has developed a reputation as a visionary strategist, a dynamic public speaker and writer, and as a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.

Mr. Simon received his law degree from the University of Washington in 1983 where he was a member of the Law Review and the Moot Court. He has a B.A. in history from the University of Arkansas.



Dr. Richard Hausmann

CEO, Elekta

Dr. Richard Hausmann is the Chief Executive Officer and President of Elekta. Dr. Hausmann has previously acted as Vice President at General Electric Company and as Chief Executive Officer and President of the Global Magnetic Resonance (MR) Business for GE Healthcare. Previous appointments held by Dr. Hausmann have also included Head of Smart Grid Applications at Siemens Aktiengesellschaft. He has also served as the Chief Executive Officer and President of Siemens China and as Member of the extended

SPEAKERS

Management Board of Siemens AG. He has a commercial background in healthcare, serving as President and Chief Executive Officer of the Siemens Healthcare Computed Tomography (CT) division.

Dr. Hausmann has published numerous articles on modern applications of Magnetic Resonance and holds various patents related to Magnetic Resonance and Imaging. He published numerous book chapters on innovation and international management.

Dr. Hausmann holds a Ph.D. in theoretical nuclear physics from Regensburg University. During his Ph.D. work he spent a year as research assistant at the state university of New York, Stony Brook. In his free time Dr. Hausmann is a passionate collector of vintage Volkswagen cars and has built his own museum. In 2009 he organized and executed the first Vintage Volkswagen Challenge and drove in a 1949 Volkswagen beetle from Germany to Beijing, China in one month together with 15 other enthusiasts and their four vintage beetles.



Dr. Jennifer Buell

Chief Operating Officer, Agenus

Dr. Buell serves as the Chief Operating Officer and is responsible for organizational operations, including Research, Clinical Development, Manufacturing, Commercial Operations, Communications, Investor Relations and External Affairs. Since joining Agenus in 2013, Dr. Buell has served as the Head of Global R&D operations, Head of Research, and Chief Communications and External Affairs Officer. During her tenure, she helped advance the expansion of Agenus from a neoantigen vaccine company to a global, fully-integrated platform company with a unique pipeline of immune modulating antibodies, cancer vaccines, adjuvants, and adoptive cell therapies. With 20 years of biopharmaceutical R&D experience, Jennifer has extensive knowledge in advancing discovery candidates through development and experience communicating with external stakeholders including regulators, investors, and collaborators. She has a proven record of success in R&D leadership, most recently at Agenus, where she led high performing teams in advancing candidates into the clinic and delivered on key alliance collaborations. Prior to joining Agenus, Jennifer held leadership positions in R&D operations at Bristol-Myers Squibb and later was responsible for Program and Alliance Management at Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government sponsored clinical programs. Jennifer obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston.



Mr. Karl Bergman

CEO, Elypta

Mr. Karl Bergman is the Chief Executive Officer of Elypta. He previously led digitalization efforts as Chief Digital Officer at Praktikertjänst, Sweden's largest private healthcare provider. Before that, he was a Principal in Arthur D. Little's healthcare & life science practice where he spent eight years assisting clients with strategic challenges across pharma, diagnostics and medtech.

Mr. Bergman holds M.Sc. degrees in Bioengineering as well as in Innovation & Entrepreneurship from Chalmers University of Technology and an MBA from University of Cambridge.

SPEAKERS



Mr. Carlos de Sousa

CEO, Immunicum

Dr. Carlos de Sousa is the Chief Executive Officer at Immunicum. He has amassed substantial experience in the international pharmaceutical and biotechnology industry, having held a range of senior positions at companies such as Nycomed/Takeda, Pfizer, Novartis, Newron Pharmaceuticals and, most recently, as Chief Business Officer at Zealand Pharma in Denmark.

Throughout his career, Dr. de Sousa has played a major role in guiding and transitioning companies from early clinical stage to bringing a product to market. In particular, at Nycomed/Takeda, he was instrumental in driving strategic decisions regarding acquisition activities, identifying and negotiating new licensing opportunities as well as leading teams to achieve key strategic goals for the company.

Having earned his medical degree at School of Medicine, University of Lisbon, Dr. de Sousa is a medical doctor by training and holds an Executive MBA from the Stern School of Business, New York University



Mr. Sebastian Hermelin

COO & Co-Founder, WarOnCancer

Mr. Sebastian Hermelin is COO and Co-Founder of WarOnCancer, a digital health company on a mission to radically improve mental health for people affected by cancer. Sebastian is currently leading WarOnCancer's co-creation projects together with the biopharmaceutical- and healthcare industry. Amongst them the project "Blockchain to Empower Patients" which aims to better understand the potential in patient-reported data, how this can be utilised by the industry in a more efficient way and foremost - how can this data be collected in a continuous and sustainable way.

The company is currently developing the WarOnCancer App - a storytelling platform for patients, survivors and loved ones, where the members can share their journeys, be inspired by others' and share patient-reported data for research and to improve healthcare. The vision is a world where patients are seen as humans, and treated that way.

Mr. Hermelin has experience of work related to consumer retail, media and the financial sector, with the primary focus of introducing new brands to new markets and creating new concepts both on the product-, sales- and marketing side. He holds a M.Sc in industrial Engineering, specializing in Energy Systems from the Royal Institute of Technology (KTH), Sweden.

SENIOR ADVISORS FOR SALSS D.C. 2019

DR. EUGEN STEINER, Partner, HealthCap
CYNTHIA EKBERG TSAI, CEO, Healthquest
MS. MERYL COMER, Co-Founder, WomenAgainstAlzheimer's
DR. RICHARD HAUSMANN, CEO, Elekta

MR. PETER UTTERSTRÖM, Legal Counsel
DR. CHARLES F. FERRIS, Special Scientific Advisor
AMBASSADOR KARIN EHNBOM PALMQUIST, Chief of Protocol

ORGANIZING COMMITTEE

BARBRO C. EHNBOM, Founder & Chairman
YLVA NICOLAE SANTESSON, Senior Project Director
CECILIA VÄRENDH MÅNSSON, Executive Administrative Coordinator
HANNA CARLZON, Interim Project Manager

SALSS ON SOCIAL MEDIA

OUR PREFERRED HASHTAGS

#salssDC2019 #swedish-americanlifesciencesummit
#investinlifescience #womeninlifescience #precisionmedicine #healthtech